Valeant Pharmaceuticals (VRX): Investor Focus Shifting To Growth Areas - Stifel

Stifel analyst, Annabel Samimy, reiterated her Buy rating on shares of Valeant Pharmaceuticals (NYSE: VRX) on the belief that now that debt has been paid down, investors can refocus on the company's growth areas.

VRX has moved diligently towards its debt pay down target of $5bn by early 2018. and the analyst believes that goal is now in reach from additional divestitures and free cash flow. Consequently, she believes investors will be shifting attention to the performance of its core franchises—
Ophthalmology (B+L), Consumer, Dermatology, and GI. Based on prescription trends, she believes that results are mixed, with GI starting to regain traction but Dermatology still struggling to regain volumes.

No change to the target of $35.

For an analyst ratings summary and ratings history on Valeant Pharmaceuticals click here. For more ratings news on Valeant Pharmaceuticals click here.

Shares of Valeant Pharmaceuticals closed at $17.24 yesterday.

You May Also Be Interested In

• Canaccord says eVTOL TAM could be worth almost $58bn by 2033
• Chervon Holdings Ltd (2285:HK) PT Lowered to HK$45 at JPMorgan
• Shiseido Co Ltd. (4911:JP) (SSDOY) PT Raised to JPY7,300 at JPMorgan